secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Oncology Therapeutics, Inc. (BBOT)
CIK:        0001869105
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001193125-26-126493
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio Oncology appoints Peter Lebowitz as independent director; NCG, Compensation committees; option grant
--------------------------------------------------------------------------------

- Board size increased to nine; Lebowitz appointed as Class I director.
- Lebowitz is independent and serves on NCG and Compensation committees.
- Received one-time option for 63,350 shares at $8.72/share (closing price on 3/24/2026).
- Standard indemnification agreement executed covering expenses from board service.
- No disclosable transactions under Reg S-K Item 404(a) involving Lebowitz.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1869105/000119312526126493/0001193125-26-126493-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1869105/000119312526126493/d126641d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-126493

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer